EPISODE · Jul 7, 2017 · 14 MIN
Should Metabolic Imaging to Assess Minimal Residual Disease (MRD) Become a Clinical Endpoint in Multiple Myeloma?
from Journal of Clinical Oncology (JCO) Podcast · host Jesus F. San Miguel
Normalization of PET-CT is a strong predictor for progression free survival (PFS) and overall survival (OS) in multiple myeloma (MM) Related Article: Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study
NOW PLAYING
Should Metabolic Imaging to Assess Minimal Residual Disease (MRD) Become a Clinical Endpoint in Multiple Myeloma?
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m